Costa JR, et al. - Researchers assessed the performance of the Absorb bioresorbable vascular scaffolds at 3 years for the treatment of low/moderate-complexity patients enrolled in the ABSORB EXTEND trial, a prospective, single-arm, open-label clinical study with 812 patients at 56 sites. Lesions ≤28 mm in length and a reference vessel diameter of 2.0-3.8 mm (as assessed by on-line QCA) were included. Average age of participants was 61 years and diabetes was present in 26.5%. Single target lesion was seen in most patients (92.4%). In 14.2% of the participants, adequate scaffold deployment (PSP) was achieved. At 3-year follow up, the link between using ABSORB in low/moderate complex PCI and low and acceptable rates of major adverse clinical events was reported, even with infrequent use of the recommended contemporary scaffold deployment technique. A higher scaffold thrombosis rate was observed vs that reported with the current generation of metallic DES.